Ginkgo Bioworks Holdings, Inc.
General ticker "DNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $554.0M (TTM average)
Ginkgo Bioworks Holdings, Inc. follows the US Stock Market performance with the rate: 38.9%.
Estimated limits based on current volatility of 3.0%: low 9.54$, high 10.14$
Factors to consider:
- Total employees count: 834 (-31.5%) as of 2024
- Top business risk factors: Cost increases, Customer dependency, Organizational changes, Litigation risks, Acquisition/divestiture risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.45$, 16.34$]
- 2025-12-31 to 2026-12-31 estimated range: [5.43$, 15.72$]
Financial Metrics affecting the DNA estimates:
- Negative: with PPE of -1.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -64.76 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 42.53 < Shareholder equity ratio, % of 51.98 <= 64.17
- Positive: -14.19 < Investing cash flow per share per price, % of -12.61
Short-term DNA quotes
Long-term DNA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $477.71MM | $251.46MM | $227.04MM |
| Operating Expenses | $2,686.66MM | $1,115.86MM | $786.80MM |
| Operating Income | $-2,208.95MM | $-864.41MM | $-559.76MM |
| Non-Operating Income | $87.55MM | $-28.53MM | $12.25MM |
| Interest Expense | $0.11MM | $0.09MM | $0.09MM |
| R&D Expense | $1,052.64MM | $580.62MM | $424.06MM |
| Income(Loss) | $-2,121.40MM | $-892.94MM | $-547.51MM |
| Taxes | $-15.03MM | $-0.07MM | $-0.48MM |
| Profit(Loss)* | $-2,104.93MM | $-892.87MM | $-547.03MM |
| Stockholders Equity | $1,736.28MM | $1,097.15MM | $716.06MM |
| Inventory | $4.36MM | $0.05MM | $0.00MM |
| Assets | $2,539.32MM | $1,665.34MM | $1,377.45MM |
| Operating Cash Flow | $-252.20MM | $-295.50MM | $-319.58MM |
| Capital expenditure | $52.27MM | $40.80MM | $62.54MM |
| Investing Cash Flow | $-67.39MM | $-80.69MM | $-62.24MM |
| Financing Cash Flow | $95.34MM | $-3.22MM | $-1.74MM |
| Earnings Per Share** | $-50.20 | $-18.40 | $-10.54 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.